Cargando…

Genetic evaluation of BRCA1-A complex genes with triple-negative breast cancer susceptibility in Chinese women

BACKGROUND: The tumor suppressor BRCA1 plays a pivotal role in maintaining genomic stability and tumor suppression. The BRCA1-A complex is required for recruitment of BRCA1 to DNA damage sites, DNA repair and cell cycle checkpoint control. Since germline mutations of BRCA1 often lead to breast tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Hong, Li, Shan, Wu, Yang, Zheng, Yi-Zi, Qiao, Feng, Yao, Ling, Cao, Zhi-Gang, Ye, Fu-Gui, Wu, Jiong, Hu, Xin, Wang, Bin, Shao, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891082/ https://www.ncbi.nlm.nih.gov/pubmed/26848770 http://dx.doi.org/10.18632/oncotarget.7112

Ejemplares similares

Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk
por: Lang, Guan-Tian, et al.
Publicado: (2020)

High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer
por: Chen, Li, et al.
Publicado: (2015)

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017)

High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer
por: Cao, Zhi-Gang, et al.
Publicado: (2016)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients
por: Lin, Yanping, et al.
Publicado: (2009)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
por: Chen, Haixia, et al.
Publicado: (2018)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People’s Republic of China
por: Ma, Fang-Jing, et al.
Publicado: (2014)

ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression
por: Li, Kai, et al.
Publicado: (2014)

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial
por: Yu, Ke-Da, et al.
Publicado: (2020)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women
por: Hao, Shuang, et al.
Publicado: (2015)

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer
por: Cao, Wen-Ming, et al.
Publicado: (2016)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

The role of BRCA status on prognosis in patients with triple-negative breast cancer
por: Xie, Yuxin, et al.
Publicado: (2017)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Homologous recombination deficiency and glycolysis‐related pathway in adjuvant chemotherapy for triple‐negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial
por: Zhu, Si‐Yuan, et al.
Publicado: (2021)

Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
por: Tong, Ling, et al.
Publicado: (2023)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer
por: Fang, Weimin, et al.
Publicado: (2023)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors
por: Darbeheshti, Farzaneh, et al.
Publicado: (2018)

Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer
por: Emborgo, Trisha S, et al.
Publicado: (2020)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Risk of metastasis in BRCA2 carriers diagnosed with triple‐negative breast cancer
por: Moreno, Marcelo, et al.
Publicado: (2023)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers
por: Li, Ang, et al.
Publicado: (2022)

A recessive variant of XRCC4 predisposes to non-BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization
por: He, Min, et al.
Publicado: (2014)

Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice
por: Zhang, Hang, et al.
Publicado: (2023)

BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells
por: Ma, Bin, et al.
Publicado: (2020)

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
por: Teo, Zhi Ling, et al.
Publicado: (2023)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer
por: Lian, Bi, et al.
Publicado: (2020)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_maeebrdf47tjd8lp6cm4709csg